APOA1 and Alzheimer disease: Intriguingly, in the APP23 transgenic mouse model of AD, an eight-week chronic intravenous administration of recombinant APOA-I Milano led to a significant reduction in cerebral amyloid load, accompanied by reduced expression of neuroinflammatory markers [156].